	US 11,857,544 B2
	Composition or method including (t)ew-7197 for treating or preventing corneal endothelial diseases
Noriko Koizumi, Kyotanabe (JP); Naoki Okumura, Kyotanabe (JP); and Mayumi Yamamoto, Osaka (JP)
Assigned to THE DOSHISHA, Kyoto (JP); and SENJU PHARMACEUTICAL CO., LTD., Osaka (JP)
Appl. No. 16/772,384
Filed by THE DOSHISHA, Kyoto (JP); and SENJU PHARMACEUTICAL CO., LTD., Osaka (JP)
PCT Filed Dec. 13, 2018, PCT No. PCT/JP2018/045919 § 371(c)(1), (2) Date Jun. 12, 2020, PCT Pub. No. WO2019/117254, PCT Pub. Date Jun. 20, 2019.
Claims priority of application No. 2017-239049 (JP), filed on Dec. 13, 2017; and application No. 2018-184783 (JP), filed on Sep. 28, 2018.
Prior Publication US 2021/0077476 A1, Mar. 18, 2021
Int. Cl. A61K 31/444 (2006.01); A61P 27/02 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 47/02 (2006.01)

CPC A61K 31/444 (2013.01) [A61K 9/0048 (2013.01); A61K 9/08 (2013.01); A61K 47/02 (2013.01); A61P 27/02 (2018.01)]

10 Claims

1. A method for treating or preventing a corneal endothelial condition, disorder, or disease, comprising administering to the subject an effective amount of (T)EW-7197 (N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), or a pharmaceutically acceptable salt thereof, or a solvate thereof.